Supplementation of creatine and ribose prevents apoptosis and right ventricle hypertrophy in hypoxic hearts

Current Pharmaceutical Design

Volumn 19, Issue 39, 2013, Pages 6873-6879

  Caretti, Anna ^a   Bianciardi, Paola ^a   Marini, Marina ^b   Abruzzo, Provvidenza M ^b   Bolotta, Alessandra ^b   Terruzzi, Carlo ^c   Lucchina, Franco ^c   Samaja, Michele ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c Giellepi Chemicals   (Italy)

Author keywords

Akt; AMPK; Apoptosis; Creatine; Hypoxia; Pulmonary endothelium; Ribose; Right vs left ventricle

Indexed keywords

ADENYLATE KINASE; CREATININE; ENDOTHELIN 1; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; RIBOSE; STRESS ACTIVATED PROTEIN KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CONTROLLED STUDY; HEART MUSCLE ISCHEMIA; HEART RIGHT VENTRICLE HYPERTROPHY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; APOPTOSIS; BASE SEQUENCE; BLOTTING, WESTERN; CELL HYPOXIA; CREATINE; DNA PRIMERS; HYPERTROPHY, RIGHT VENTRICULAR; MALE; MICE; MICE, INBRED ICR; REAL-TIME POLYMERASE CHAIN REACTION; RIBOSE; SIGNAL TRANSDUCTION;

EID: 84889013549     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161281939131127114218     Document Type: Article

References (48)

1. Samaja M. Prediction of the oxygenation of human organs at varying blood oxygen carrying properties. Respir Physiol 1988; 72: 211-8.
2. Sharov V, Saks V, Kupriyanov V, et al. Protection of ischemic myiocardium by exogenus phosphocreatine. J Thorac Cardiovasc Surg 1987; 94: 749-61.
3. Constantin-Teodosiu D, Greenhaff PL, Gardiner SM, Randall MD, March JE, Bennett T. Attenuation by creatine of myocardial metabolic stress in Brattleboro rats caused by chronic inhibition of nitric oxide synthase. Br J Pharmacol 1995; 116(8): 3288-92.
4. Hamman B, Bittl J, Jacobus W, et al. Inhibition of the creatine kinase reaction decreases the contractile reserve of isolated rat hearts. Am J Physiol 1995; 269: H1030-H6.
5. Omran H, Illien S, MacCarter D, St Cyr J, Luderitz B. D-Ribose improves diastolic function and quality of life in congestive heart failure patients: a prospective feasibility study. Eur J Heart Fail 2003; 5(5): 615-9.
6. Pliml W, von Arnim T, Stablein A, Hofmann H, Zimmer HG, Erdmann E. Effects of ribose on exercise-induced ischaemia in stable coronary artery disease. Lancet 1992; 340(8818): 507-10.
7. Wallen WJ, Belanger MP, Wittnich C. Preischemic administration of ribose to delay the onset of irreversible ischemic injury and improve function: studies in normal and hypertrophied hearts. Can J Physiol Pharmacol 2003; 81(1): 40-7.
8. Caretti A, Bianciardi P, Sala G, Terruzzi C, Lucchina F, Samaja M. Supplementation of creatine and ribose prevents apoptosis in ischemic cardiomyocytes. Cell Physiol Biochem 2010; 26(6): 831-8. Epub 2011/01/12.
9. Milano G, Corno AF, Samaja M, Morel S, Vassalli G, von Segesser LK. Daily reoxygenation decreases myocardial injury and improves post-ischaemic recovery after chronic hypoxia. Eur J Cardiothorac Surg 2010; 37(4): 942-9.
10. Milano G, Bianciardi P, Corno AF, et al. Myocardial impairment in chronic hypoxia is abolished by short aeration episodes: involvement of K+ATP channels. Exp Biol Med (Maywood) 2004; 229(11): 1196-205.
11. Milano G, Bianciardi P, Rochemont V, et al. Phosphodiesterase-5 inhibition mimics intermittent reoxygenation and improves cardioprotection in the hypoxic myocardium. PLoS One 2011; 6(11): e27910.
12. Morel S, Milano G, Ludunge KM, et al. Brief reoxygenation episodes during chronic hypoxia enhance posthypoxic recovery of LV function: Role of mitogen-activated protein kinase signaling pathways. Basic Res Cardiol 2006; 101(4): 336-45.
13. Caretti A, Morel S, Milano G, et al. Heart HIF-1alpha and MAP kinases during hypoxia: are they associated in vivo? Exp Biol Med (Maywood) 2007; 232(7): 887-94.
14. Milano G, von Segesser LK, Morel S, et al. Phosphorylation of phosphatidylinositol-3-kinase-protein kinase B and extracellular signal-regulated kinases 1/2 mediate reoxygenation-induced cardioprotection during hypoxia. Exp Biol Med (Maywood) 2010; 235(3): 401-10.
15. Bianciardi P, Fantacci M, Caretti A, et al. Chronic in vivo hypoxia in various organs: hypoxia-inducible factor-1alpha and apoptosis. Biochem Biophys Res Commun 2006; 342(3): 875-80.
16. Sylvester JT, Shimoda LA, Aaronson PI, Ward JP. Hypoxic pulmonary vasoconstriction. Physiol Rev 2012; 92(1): 367-520.
17. Fonseca C, Abraham D, Renzoni EA. Endothelin in pulmonary fibrosis. Am J Respir Cell Mol Biol 2011; 44(1): 1-10.
18. Corno AF, Milano G, Samaja M, Tozzi P, von Segesser LK. Chronic hypoxia: a model for cyanotic congenital heart defects. J Thorac Cardiovasc Surg 2002; 124(1): 105-12.
19. Tagliavacca L, Caretti A, Bianciardi P, Samaja M. In vivo upregulation of the unfolded protein response after hypoxia. Biochim Biophys Acta 2012; 1820(7): 900-6.
20. Abruzzo PM, Di Tullio S, Marchionni C, et al. Oxidative stress in the denervated muscle. Free Radic Res 2010; 44(5): 563-76.
21. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001; 29(9): e45.
22. Corno AF, Milano G, Morel S, et al. Hypoxia: unique myocardial morphology? J Thorac Cardiovasc Surg 2004; 127(5): 1301-8.
23. Adrogue JV, Sharma S, Ngumbela K, Essop MF, Taegtmeyer H. Acclimatization to chronic hypobaric hypoxia is associated with a differential transcriptional profile between the right and left ventricle. Mol Cell Biochem 2005; 278(1-2): 71-8.
24. Kitahori K, He H, Kawata M, et al. Development of left ventricular diastolic dysfunction with preservation of ejection fraction during progression of infant right ventricular hypertrophy. Circ Heart Fail 2009; 2(6): 599-607.
25. Gurusamy N, Das DK. Autophagy, redox signaling, and ventricular remodeling. Antioxid Redox Signal 2009; 11(8): 1975-88.
26. Vigano A, Vasso M, Caretti A, et al. Protein modulation in mouse heart under acute and chronic hypoxia. Proteomics 2011; 11(21): 4202-17.
27. Kammermeier H. Why do cells need phosphocreatine and a phosphocreatine shuttle. J Mol Cell Cardiol 1987; 19: 115-8.
28. Smolenski RT, Kalsi KK, Zych M, Kochan Z, Yacoub MH. Adenine/ribose supply increases adenosine production and protects ATP pool in adenosine kinase-inhibited cardiac cells. J Mol Cell Cardiol 1998; 30(3): 673-83.
29. Hanada M, Feng J, Hemmings BA. Structure, regulation and function of PKB/AKT-a major therapeutic target. Biochim Biophys Acta 2004; 1697(1-2): 3-16.
30. Soltys CL, Kovacic S, Dyck JR. Activation of cardiac AMPactivated protein kinase by LKB1 expression or chemical hypoxia is blunted by increased Akt activity. Am J Physiol Heart Circ Physiol 2006; 290(6): H2472-9.
31. Levine YC, Li GK, Michel T. Agonist-modulated regulation of AMP-activated protein kinase (AMPK) in endothelial cells. Evidence for an AMPK-> Rac1-> Akt-> endothelial nitric-oxide synthase pathway. J Biol Chem 2007; 282(28): 20351-64.
32. Nagata D, Mogi M, Walsh K. AMP-activated protein kinase (AMPK) signaling in endothelial cells is essential for angiogenesis in response to hypoxic stress. J Biol Chem 2003; 278(33): 31000-6.
33. Ouchi N, Kobayashi H, Kihara S, et al. Adiponectin stimulates angiogenesis by promoting cross-talk between AMP-activated protein kinase and Akt signaling in endothelial cells. J Biol Chem 2004; 279(2): 1304-9.
34. Sussman MA, Volkers M, Fischer K, et al. Myocardial AKT: the omnipresent nexus. Physiol Rev 2011; 91(3): 1023-70.
35. Pachori AS, Smith A, McDonald P, Zhang L, Dzau VJ, Melo LG. Heme-oxygenase-1-induced protection against hypoxia/reoxygenation is dependent on biliverdin reductase and its interaction with PI3K/Akt pathway. J Mol Cell Cardiol 2007; 43(5): 580-92.
36. Mukherjee S, Lekli I, Das M, Azzi A, Das DK. Cardioprotection with alpha-tocopheryl phosphate: Amelioration of myocardial ischemia reperfusion injury is linked with its ability to generate a survival signal through Akt activation. Biochim Biophys Acta 2008; 1782: 498-503.
37. Heineke J, Molkentin JD. Regulation of cardiac hypertrophy by intracellular signalling pathways. Nat Rev Mol Cell Biol 2006; 7(8): 589-600.
38. Rigor DL, Bodyak N, Bae S, et al. Phosphoinositide 3-kinase Akt signaling pathway interacts with protein kinase Cbeta2 in the regulation of physiologic developmental hypertrophy and heart function. Am J Physiol Heart Circ Physiol 2009; 296(3): H566-72.
39. Luckey SW, Walker LA, Smyth T, et al. The role of Akt/GSK-3beta signaling in familial hypertrophic cardiomyopathy. J Mol Cell Cardiol 2009; 46(5): 739-47.
40. Yu C, Minemoto Y, Zhang J, et al. JNK suppresses apoptosis via phosphorylation of the proapoptotic Bcl-2 family protein BAD. Mol Cell 2004; 13(3): 329-40.
41. Yamamoto K, Ichijo H, Korsmeyer SJ. BCL-2 is phosphorylated and inactivated by an ASK1/Jun N-terminal protein kinase pathway normally activated at G(2)/M. Mol Cell Biol 1999; 19(12): 8469-78.
42. Tournier C, Hess P, Yang DD, et al. Requirement of JNK for stress-induced activation of the cytochrome c-mediated death pathway. Science 2000; 288(5467): 870-4.
43. Deng Y, Ren X, Yang L, Lin Y, Wu X. A JNK-dependent pathway is required for TNFalpha-induced apoptosis. Cell 2003; 115(1): 61-70.
44. Aikin R, Maysinger D, Rosenberg L. Cross-talk between phosphatidylinositol 3-kinase/AKT and c-jun NH2-terminal kinase mediates survival of isolated human islets. Endocrinology 2004; 145(10): 4522-31.
45. Kefas BA, Cai Y, Ling Z, et al. AMP-activated protein kinase can induce apoptosis of insulin-producing MIN6 cells through stimulation of c-Jun-N-terminal kinase. J Mol Endocrinol 2003; 30(2): 151-61.
46. Wei J, Wang W, Chopra I, et al. c-Jun N-terminal kinase (JNK-1) confers protection against brief but not extended ischemia during acute myocardial infarction. J Biol Chem 2011; 286(16): 13995-4006.
47. Chiu CZ, Wang BW, Chung TH, Shyu KG. Angiotensin II and the ERK pathway mediate the induction of myocardin by hypoxia in cultured rat neonatal cardiomyocytes. Clin Sci (Lond) 2010; 119(7): 273-82.
48. Jones NM, Bergeron M. Hypoxia-induced ischemic tolerance in neonatal rat brain involves enhanced ERK1/2 signaling. J Neurochem 2004; 89(1): 157-67.